Skip to main content

Redmile Group — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

104
Companies
$12.1B
Total invested
$128.9M
Avg. check
16
Industries
Biotechnology 22Health Care 14Therapeutics 12Medical 11Pharmaceutical 7Biopharma 5+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 104
Atara Biotherapeutics
May 2025

Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.

Biotechnology · South San Francisco$16.0M Post Ipo Equity
Attovia Therapeutics
April 2025

Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.

Biotechnology · San Carlos$90.0M Series C
Replimune Group
November 2024

Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.

Biotechnology · Woburn$140.0M Post Ipo Equity
CorVent Medical
June 2024

We provide simple, sophisticated respiratory solutions for post-ICU and home environments, eliminating unnecessary cost and complexity.

Health Care · Fargo$3.0M Grant
Gritstone bio
April 2024

Gritstone bio is a biotechnology company that develops immunotherapies for cancer and infectious diseases.

Biotechnology · Emeryville$32.5M Post Ipo Equity
Attralus
February 2024

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.

Biopharma · San Francisco$56.0M Series B
EmployerDirect Healthcare
December 2023

EmployerDirect Healthcare is a supplemental healthcare benefit that directs planned medical procedures to high-quality providers.

Health Care · Dallas$92.0M Secondary Market
IGM Biosciences
June 2023

IGM Biosciences is a biotechnology company that develops medicine for people with infectious infections, autoimmune diseases, and cancer.

Biotechnology · Mountain View$107.3M Post Ipo Equity
Zentalis Pharmaceuticals
June 2023

Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.

Biopharma · New York$235.5M Post Ipo Equity
Krystal Biotech
May 2023

Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..

Biopharma · Pittsburgh$160.0M Post Ipo Equity
OncoResponse
May 2023

OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.

Biopharma · Seattle$14.0M Series D
Orbital Therapeutics
April 2023

Orbital Therapeutics is a biotechnology company that develops RNA-based medicines to treat disease in humans.

Alternative Medicine · Cambridge$270.0M Series A
MedAvail
March 2023

MedAvail focuses on the discovery, development, and commercialization of advanced nutrition products.

Biotechnology · Mississauga$16.0M Post Ipo Equity
Pliant Therapeutics
January 2023

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Biotechnology · South San Francisco$287.5M Post Ipo Equity
Escient Pharmaceuticals
November 2022

Escient Pharmaceuticals is a privately-held biotechnology company focusing on the advancement of G Protein-Coupled Receptor targeted drugs.

Biotechnology · San Diego$120.0M Series C
Achilles Therapeutics
July 2022

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

Biotechnology · London$4.1M Grant
Home Biosciences
November 2021

Home Biosciences is a European venture builder dedicated to biotech.

Biotechnology · Paris$15.0M Seed
Sphere Bio
October 2021

Sphere Bio specializes in tools for single cell analysis and isolation, facilitating discovery in the biotech field.

Biotechnology · Cambridge$41.4M Series Unknown
Repare Therapeutics
October 2021

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.

Biotechnology · Saint Laurent$101.2M Post Ipo Equity
Zentera Therapeutics
August 2021

Zentera Therapeutics is a biopharmaceutical company.

Biotechnology · Shanghai$75.0M Series B
Mnemo Therapeutics
June 2021

Mnemo Therapeutics specializes in biotechnology and life science.

Biotechnology · Paris$90.0M Series A
Ayala Pharmaceuticals
February 2021

Ayala Pharmaceuticals a clinical-stage biopharmaceutical company focused on developing and commercializing small molecule therapeutics.

Biotechnology · Wilmington$25.0M Post Ipo Equity
Lava Therapeutics
September 2020

Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.

Biotechnology · Utrecht$83.0M Series C
Aurinia Pharmaceuticals
July 2020

Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.

Biopharma · Victoria$200.0M Post Ipo Equity

Where Redmile Group invests

Biotechnology22
Health Care14
Therapeutics12
Medical11
Pharmaceutical7
Biopharma5

About Redmile Group's portfolio

How many companies has Redmile Group invested in?

Redmile Group has invested in 104 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Redmile Group invest in?

Redmile Group's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 16 different industry categories.

What is Redmile Group's largest investment?

Among tracked funding rounds, Pliant Therapeutics received $287.5M in a Post Ipo Equity round. Redmile Group's total known invested capital is $12.1B.

What is the average investment size for Redmile Group?

Redmile Group's average investment size is $128.9M across its portfolio of 104 companies.

What are Redmile Group's most recent investments?

Recent Redmile Group portfolio additions include Atara Biotherapeutics, Attovia Therapeutics, Replimune Group, CorVent Medical, Gritstone bio. These companies were founded in 2020 or later.

Reach the founders behind these 104 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →